USP Establishes Elemental Impurities Implementation Dates
USP announces an implementation date of Jan. 1, 2018 for General Chapters Elemental Impurities-Limits and Elemental Contaminants in Dietary Supplements.
The United States Pharmacopeial Convention (USP) announced on Mar. 31, 2015 that it would establish Jan. 1, 2018 as the implementation date for General Chapters <232> Elemental Impurities-Limits and <2232> Elemental Contaminants in Dietary Supplements in USP’s compendia of public standards, United States Pharmacopeia–National Formulary (USP–NF). The announcement also confirmed that USP would remove General Chapter <231> Heavy Metals from USP–NF, and monograph references to this chapter will be delayed until the aforementioned date in 2018.
Users may continue to use the current approach or implement the new 232/2232 approaches until Jan. 1, 2018, on which date the General Chapters will be required unless otherwise specified in a monograph. USP revised General Notices Section 5.60.30 Elemental Impurities in USP Drug Products and Dietary Supplements in USP–NF following the December 2014 release of the International Conference on Harmonization (ICH) Q3D Guideline for Elemental Impurities, and based on dialogue with industry representatives and FDA. The revisions are official as of Apr. 1, 2015 and are listed in the press release as follows:
- Specify the timing of the applicability of General Chapters <232> and <2232> for Jan. 1, 2018 to align more closely with the implementation date of the ICH Q3D guideline for existing products.
- Note the delay in omission of General Chapter <231> Heavy Metals until Jan. 1, 2018 to align with the applicability of <232>.
- Allow early adoption of the General Chapters <232> and <2232> in the interim to enable users to determine whether to use the existing <231> or the new <232>/<2232> approaches.
Source: USP
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
